Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
TECHNOLOGY
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
JIM CRAMER
Resilient Bull: Cramer's 'Mad Money' Recap (Wednesday 1/8/20)
By Scott Rutt
Jan 8, 2020 9:24 PM EST
PRESS RELEASES
Apellis And Sobi: The New England Journal Of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan To Eculizumab For PNH
By GlobeNewswire
Mar 17, 2021 5:48 PM EDT
PRESS RELEASES
Apellis Announces Two New Publications From The Positive Phase 2 FILLY Study Evaluating Pegcetacoplan In Geographic Atrophy
By GlobeNewswire
Mar 10, 2021 9:15 AM EST
PRESS RELEASES
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By GlobeNewswire
Mar 5, 2021 4:05 PM EST
PRESS RELEASES
Apellis Provides Update On APL-9 For Severe COVID-19
By GlobeNewswire
Mar 4, 2021 4:05 PM EST
PRESS RELEASES
Apellis Pharmaceuticals To Present At Upcoming Investor Conferences
By GlobeNewswire
Feb 22, 2021 8:00 AM EST
PRESS RELEASES
Apellis Pharmaceuticals To Hold Fourth Quarter And Full Year 2020 Earnings Conference Call On February 25, 2021
By GlobeNewswire
Feb 18, 2021 4:05 PM EST
PRESS RELEASES
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By GlobeNewswire
Feb 5, 2021 4:05 PM EST
PRESS RELEASES
Apellis Pharmaceuticals To Host Investor Event On Geographic Atrophy On January 28, 2021
By GlobeNewswire
Jan 21, 2021 7:00 AM EST
PRESS RELEASES
Apellis Pharmaceuticals To Present At The 39th Annual J.P. Morgan Healthcare Conference
By GlobeNewswire
Jan 5, 2021 7:00 AM EST
PRESS RELEASES
Apellis And Sobi Report Positive Top-line Results At 48 Weeks From The Phase 3 PEGASUS Study Of Pegcetacoplan In PNH
By GlobeNewswire
Dec 10, 2020 6:00 AM EST
PRESS RELEASES
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By GlobeNewswire
Dec 4, 2020 4:05 PM EST
PRESS RELEASES
Apellis Pharmaceuticals To Present At The 2020 Evercore ISI HealthCONx Conference
By GlobeNewswire
Nov 30, 2020 7:00 AM EST
PRESS RELEASES
Apellis And Sobi Announce First Patient Dosed In Potentially Registrational ALS Study Of Pegcetacoplan
By GlobeNewswire
Nov 19, 2020 6:45 AM EST
PRESS RELEASES
Apellis Announces Late-Breaking Presentation Of Largest Retrospective Database Study In Geographic Atrophy (GA) At AAO 2020 Virtual
By GlobeNewswire
Nov 13, 2020 10:40 AM EST
PRESS RELEASES
Apellis Pharmaceuticals To Present At Upcoming Investor Conferences
By GlobeNewswire
Nov 11, 2020 7:00 AM EST
PRESS RELEASES
Apellis To Present New Data Supporting The Efficacy And Safety Of Pegcetacoplan In PNH At The American Society Of Hematology Annual Meeting
By GlobeNewswire
Nov 5, 2020 7:00 AM EST
PRESS RELEASES
Apellis To Present Positive Results From The Phase 2 DISCOVERY Study Of Pegcetacoplan In C3 Glomerulopathy (C3G) At ASN Kidney Week
By GlobeNewswire
Oct 9, 2020 10:14 AM EDT
PRESS RELEASES
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By GlobeNewswire
Oct 7, 2020 4:05 PM EDT
PRESS RELEASES
Apellis Initiates Registrational Programs Of Pegcetacoplan In Patients With C3G / IC-MPGN And ALS, Rare Diseases With High Unmet Need
By GlobeNewswire
Oct 5, 2020 7:00 AM EDT
PRESS RELEASES
Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression Of Early Disease In Patients With Geographic Atrophy (GA)
By GlobeNewswire
Oct 3, 2020 11:05 AM EDT
PRESS RELEASES
Apellis Pharmaceuticals To Present At Stifel's 2020 Immunology And Inflammation Virtual Summit
By GlobeNewswire
Sep 24, 2020 4:05 PM EDT
PRESS RELEASES
Apellis Announces Late-Breaking Presentation Of Targeted C3 Therapy Pegcetacoplan In Patients With Geographic Atrophy (GA) At EURETINA 2020
By GlobeNewswire
Sep 21, 2020 4:05 PM EDT
PRESS RELEASES
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By GlobeNewswire
Sep 4, 2020 4:05 PM EDT
PRESS RELEASES
Apellis Pharmaceuticals To Present At Upcoming Investor Conferences
By GlobeNewswire
Sep 2, 2020 7:00 AM EDT